Incyte completes acquisition of Escient Pharmaceuticals to strengthen its Inflammation and Autoimmunity portfolio
Acquiring Company
Incyte Corporation
Acquired Company
Escient Pharmaceuticals
WilmingtonSan DiegoBiotechnologyTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Incyte has successfully completed the acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company that focuses on novel small molecule therapeutics. This acquisition strengthens Incyte's commitment to creating innovative solutions for severe inflammatory diseases and bolsters its Inflammation and Autoimmunity portfolio, adding EP262 and EP547 to its portfolio.
Quick answer
Incyte Corporation is acquiring Escient Pharmaceuticals, announced May 30, 2024. Incyte Corporation is based in Wilmington, Delaware, United States.
- How much did Incyte Corporation pay for Escient Pharmaceuticals?
- The deal value was not disclosed.
- What does Incyte Corporation do?
- Incyte is a global biopharmaceutical company focused on advancing innovative medicines through deep scientific expertise and a patient-centered approach.
- Where are Incyte Corporation and Escient Pharmaceuticals based?
- Incyte Corporation is based in Wilmington, Delaware, United States. Escient Pharmaceuticals is based in San Diego, California, United States.
- Who are the decision-makers at Incyte Corporation?
- Fundz holds 1 contact at Incyte Corporation. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio (July 8, 2024)
- Future Pak proposes acquisition of Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash (April 17, 2024)
- Lilly completes acquisition of Morphic to enhance immunology pipeline (July 8, 2024)
Who to call at Incyte Corporation, and when
When Incyte Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Incyte Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Incyte Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Incyte Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Incyte Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Escient Pharmaceuticals?
Escient Pharmaceuticals was acquired by Incyte Corporation, based in Wilmington. The deal was reported on May 30, 2024. Incyte is a global biopharmaceutical company focused on advancing innovative medicines through deep scientific expertise and a patient-centered approach. Incyte Corporation is publicly traded (INCY) and operates in Biotechnology.
When did Incyte Corporation acquire Escient Pharmaceuticals?
Incyte Corporation's acquisition of Escient Pharmaceuticals was reported on May 30, 2024. Incyte has successfully completed the acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company that focuses on novel small molecule therapeutics. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Escient Pharmaceuticals do?
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.